|

LN-145 Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since May 2026

Also known as: Autologous Tumor Infiltrating Lymphocytes, TIL, Autologous Tumor Infiltrating Lymphocytes, TIL, autologous tumor infiltrating lymphocytes

Pipeline

Phase 2: 2

Top Sponsors

  • Karam Khaddour, MD, MS1
  • Iovance Biotherapeutics, Inc.1

Indications

  • Cancer2
  • Metastatic Cutaneous Squamous Cell Carcinoma1
  • Skin Cancer1
  • Cutaneous Squamous Cell Carcinoma1
  • Metastatic Non-Small Cell Lung Cancer1

Gilbert, Arizona1 trial

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Banner Health MD Anderson

Phase 2

Boston, Massachusetts1 trial

TIL Therapy in cSCC and MCC

Dana-Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.